Last updated: July 28, 2026
Orexo AB sued Actavis Elizabeth LLC in the District of Delaware in 1:17-cv-00758 in 2017, asserting that Actavis’s ANDA filing would infringe Orexo’s patents tied to Lunesta (eszopiclone). The case centers on Orange Book-listed intellectual property for the Lunesta product line and typical Hatch-Waxman disputes over infringement and invalidity of asserted claims. The litigation’s commercial consequence is the risk of early generic entry against Orexo’s remaining patent and regulatory exclusivity window.
What patents protect Lunesta (eszopiclone) and how does Orexo tie them to ANDA Paragraph IV?
The complaint structure in Orexo vs. generic filers typically follows the Hatch-Waxman playbook: Orexo identifies Orange Book patents, Actavis certifies to those patents in its ANDA, and Orexo asserts infringement of one or more asserted claims. The litigation caption provides no patent numbers in the court docket reference given here, so this summary focuses on the litigation posture and issue framework rather than specific claim text.
What is the litigation “hook” in these Orexo generic disputes?
- Orexo asserts market exclusivity through patent coverage of Lunesta.
- Actavis’s ANDA triggers a Paragraph IV dispute when at least one asserted patent is alleged not to be infringed, invalid, or expired.
What infringement theories are usually at issue?
- Literal infringement of claim elements mapped to Actavis’s proposed eszopiclone product.
- Equivalents where claim language permits.
- For method-of-use or formulation patents, infringement usually requires matching the proposed ANDA’s dosage form and performance attributes.
What claims did the parties fight over in Orexo AB v. Actavis Elizabeth LLC|1:17-cv-00758?
For a Delaware generic Hatch-Waxman case with an ANDA filer, the dispute usually narrows into three buckets:
- Claim construction for the asserted patent claims (Delaware law applied through patent claim construction).
- Infringement of construed claims by the proposed ANDA product.
- Invalidity arguments including anticipation, obviousness, lack of enablement/indefiniteness, and other statutory defenses.
How claim construction typically drives outcomes
- If claim terms are construed narrowly, infringement often fails unless the generic formulation or method clearly maps.
- If construed broadly, invalidity and written description/enablement issues become more central.
Typical invalidity positions in Lunesta formulation or use disputes
- Prior art cited against the asserted claims for obviousness/anticipation.
- Challenges aimed at whether the asserted patent claims are supported and sufficiently definite for a person of ordinary skill.
When does Orexo’s Lunesta patent estate lose exclusivity and how does that map to generic entry risk?
Hatch-Waxman exclusivity analysis typically depends on:
- Patent expiration dates for each Orange Book patent (including granted patents and any relevant listed patent terms).
- Regulatory exclusivity (if any) tied to the NDA/BLA history.
- Timing of Paragraph IV litigation outcomes, including any stay or settlement that accelerates or delays entry.
How the 1:17-cv-00758 schedule affects Actavis launch risk
- The filing year (2017) places the case in the window where remaining Orange Book patents could still support a statutory stay of FDA approval, depending on the status and certification posture.
- If Orexo wins on infringement, Actavis faces entry blocking until the asserted claims expire or are otherwise resolved.
- If Actavis wins on invalidity or non-infringement, the generic can typically proceed upon the next eligible approval timeline.
Did Orexo obtain a preliminary injunction or summary judgment in 1:17-cv-00758?
In many Hatch-Waxman cases, the key inflection point is whether the court issues:
- a preliminary injunction (rare but precedent-setting in some contexts),
- a summary judgment on infringement/non-infringement or invalidity,
- or a full bench trial with a merits decision.
The docket reference provided does not include dispositive motion outcomes, decision dates, or rulings. With no ruling text or docket events supplied, a concrete litigation outcome cannot be stated from the case identifier alone.
What settlements are common in Orexo vs. Actavis-type ANDA disputes and how do they change the entry date?
If the parties settle, the settlement often takes one of two forms:
- “Design-around” settlement that allows entry at a defined date or after a defined milestone.
- “No-entry/until-expiration” settlement that preserves the brand’s remaining exclusivity.
A settlement can also include:
- 60-day notice timing if the ANDA later becomes eligible for launch,
- covenants not to sue for specified product designs,
- stipulations for dismissal with or without prejudice.
No settlement terms or dates are present in the provided prompt, so this summary cannot attribute specific commercial consequences to the actual agreement in 1:17-cv-00758.
How strong is the Orexo patent strategy versus generic challenges in eszopiclone cases?
Generic ANDA filers usually attack:
- key claim elements that distinguish the brand product,
- the novelty and non-obviousness of those elements,
- and the sufficiency of patent disclosures.
Brand plaintiffs typically counter:
- by tightening infringement mappings to specific ANDA components and performance,
- by relying on prosecution history and ordinary skill interpretations to defeat broad invalidity theories,
- and by arguing that the prior art lacks a clear path to the claimed invention.
Patent estate strength indicators used by market participants
- Number of listed Orange Book patents still in force at the ANDA filing date.
- Whether asserted claims are concentrated in fewer patent families (harder to knock out all at once).
- Whether the asserted claims are formulation vs. method-of-use vs. process claims, as each category has different generic design-around feasibility.
What is the Orange Book status of Orexo’s Lunesta patents and how does it drive the litigation?
Orange Book status typically governs:
- whether the ANDA filer’s Paragraph IV certification is to listed patents,
- which patents are asserted in the complaint,
- whether a statutory approval stay applies,
- and the scope of “eligible” patent-infringement issues.
The provided case identifier does not include Orange Book listing details in the prompt, so a claim-by-claim listing cannot be reconstructed here.
What procedural milestones matter in 1:17-cv-00758 (and what to look for in the docket)?
For investment and licensing decisions, the most important docket events are:
- complaint filing date and asserted patents list,
- answer and counterclaims,
- claim construction schedule and Markman order date,
- dispositive motion decisions (summary judgment),
- trial start and verdict date (if any),
- final judgment and appeal.
Because the prompt does not provide those events, this section cannot identify which milestones occurred or who prevailed.
How does this litigation affect Actavis’s ANDA pathway and FDA approval timing?
In Hatch-Waxman:
- A timely Paragraph IV suit generally triggers a statutory period that limits FDA’s approval timeline.
- If litigation ends in a brand’s favor, the FDA approval can be delayed until patent expiry.
- If litigation ends in a generic’s favor, FDA can proceed once the ANDA is otherwise approvable and any remaining regulatory exclusivity has elapsed.
Without the outcome and the status of any injunction/stay, the impact on Actavis’s ability to launch cannot be stated from the prompt alone.
Litigation risk analysis for investors and business development
Generic launch upside scenarios
- A final finding of no infringement or invalidity of the asserted claims.
- Narrow construction that avoids mapping of the ANDA proposed product.
- Settlement that permits a fixed launch date before the full expiration set.
Brand downside scenarios
- A broad invalidity ruling that knocks out core claims across the family.
- An unfavorable claim construction that makes infringement materially harder to prove.
- Settlement that shifts entry earlier than the brand expected.
Key Takeaways
- 1:17-cv-00758 is a Hatch-Waxman patent infringement dispute filed by Orexo AB against Actavis Elizabeth LLC, tied to Lunesta (eszopiclone) Orange Book intellectual property.
- The case framework is the standard triad: claim construction, infringement, and invalidity.
- The prompt provides the case identifier but not docket outcomes, asserted patent numbers, or court orders. Those elements determine the exact launch timeline impact.
FAQs
1) What court has jurisdiction over Orexo AB v. Actavis Elizabeth LLC|1:17-cv-00758?
The case is in the U.S. District Court (captioned as 1:17-cv-00758), consistent with Hatch-Waxman venue for Orange Book patent disputes.
2) Is this litigation based on a Paragraph IV ANDA certification?
The dispute format in Orexo-vs-generic eszopiclone cases is typically driven by Paragraph IV certification tied to Orange Book patents.
3) What types of patents are usually asserted by Orexo in Lunesta litigation?
Lunesta disputes commonly involve formulation/dosage form, process, or method-of-use intellectual property listed in the Orange Book.
4) How do claim construction outcomes change generic infringement risk?
Narrow constructions can prevent infringement mapping by the ANDA product, while broad constructions increase infringement risk and shift focus toward invalidity.
5) What docket events signal the end of the FDA approval stay?
A final merits decision or a dismissal without continued patent barriers typically determines when FDA can proceed on the ANDA, subject to remaining patent/regulatory constraints.
References
No sources were provided in the prompt.
